Set to enter hospice care, a patient with idiopathic multicentric Castleman鈥檚 disease is now in remission after treatment with a medication identified by an AI-guided analysis
Shoulder symptoms led to an average of 9.6 million physician visits in 2015 and 2016 in the United States.The most common cause of those shoulder symptoms?Rotator-cuff disorders.Tears of the rotator cuff can result from a substantial traumatic injury or can occur slowly over time.
A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.
鈥� Study finds three new safe and effective drug regimens to fight multidrug-resistant TB 鈥� The treatments, which include recently discovered TB drugs, give new options for shorter, personalized treatment and are cleared for use for more people than ever
The University of Chicago Medicine has launched a Phase 2 clinical trial to study how CAR T-cell therapy could be used to treat three autoimmune diseases.
Women who were cared for by the MedStar Health D.C. Safe Babies Safe Moms program (SBSM) have better outcomes in pregnancy, delivery, and postpartum, according to a study published today in NEJM Catalyst Innovations in Care Delivery.
A study led by Rutgers professor finds more liberal blood transfusions have more favorable results
A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk SMM carries a higher likelihood of progression.
Researchers at Children鈥檚 Hospital of Philadelphia (CHOP) and the Children鈥檚 Oncology Group (COG) announced the results of a Phase 3 study that demonstrated adding the bi-specific T-cell engager, blinatumomab, to chemotherapy for newly diagnosed National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) pediatric patients significantly improves survival outcomes. The results were published today in the New England Journal of Medicine and will be presented during the plenary session at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego on December 8.
Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene autoleucel (obe-cel), experienced high response rates and most did not need a subsequent stem cell transplant (SCT), according to results from the Phase Ib/II FELIX trial co-led by researchers at The University of Texas MD Anderson Cancer Center.
Embargoed Hodgkin鈥檚 Lymphoma NEJM Study: Live event with URMC - Live Event. 10/14/2024
In the United States, there are currently more adults living with cerebral palsy than children.聽Despite this, the Centers for Disease Control and Prevention still label cerebral palsy as 鈥渢he most common motor disability in childhood.鈥�
Researchers at Children鈥檚 Hospital of Philadelphia (CHOP) announced encouraging results from the first ever gene therapy trial for Danon disease (DD), a rare, X-linked heart condition caused by a single gene mutation. The phase 1 trial was a collaboration between CHOP and the University of California, San Diego Medical Center, the University of Colorado, Anschutz Medical Center, Boston Children's Hospital and Rocket Pharmaceuticals. The data on the results of the RP-A501 Phase 1 trial, presented at a late breaking session today at the American Heart Association Scientific Sessions 2024 in Chicago, were also published in the New England Journal of Medicine.
Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to a New England Journal of Medicine editorial published by Matthew Milowsky, MD, FASCO, a bladder cancer expert at UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center.
The first powered randomized trial examining early intervention with transcatheter aortic valve replacement (TAVR) in patients with asymptomatic, severe aortic stenosis (AS) found this strategy to be both a safe and effective alternative to clinical surveillance (CS). Findings were reported today at TCT 2024, the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world鈥檚 premier educational meeting specializing in interventional cardiovascular medicine. Results were also published simultaneously in the New England Journal of Medicine.
A syndrome called cachexia, which triggers unexplained loss of weight and muscle mass, causes severe illness and death among patients with cancer and other serious health conditions.
A review of what's known about the crisis in physician well-being, and what can be done to address it, also suggests a need for action by health systems, and more research.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal 海角社区 keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right